Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080, P. R. China.
Guangdong Provincial Clinical Research Center for Obstetrical and Gynecological Diseases, Guangzhou, Guangdong, 510080, P. R. China.
Adv Sci (Weinh). 2024 Oct;11(38):e2404645. doi: 10.1002/advs.202404645. Epub 2024 Aug 9.
The lymph node is the most common site of distant metastasis of cervical squamous cell carcinoma (CSCC), which elicits dismal prognosis and limited efficiency for treatment. Elucidation of the mechanisms underlying CSCC lymphatic metastasis would provide potential therapeutic strategies for nodal metastatic of CSCC. Here, based on in vivo lymphatic metastasis screening model, a circular RNA is identified that is termed as lymph node metastasis associated circRNA (LNMAC), is markedly upregulated in lymphatic metastatic CSCC and correlated with lymph node metastasis. Overexpression of LNMAC dramatically augments the metastatic capability of CSCC cells to the lymph node via inducing lymphangiogenesis. Mechanistically, LNMAC epigenetically upregulates fibroblast growth factor 2 (FGF2) expression by directly associating with histone acacetylase 1 (HDAC1), preventing Importin α6/8-mediated nuclear translocation of HDAC1 and eliciting histone H3K27ac-induced FGF2 transcriptional activation. Treatment with 3F12E7, an anti-FGF2 monoclonal antibody, effectively inhibits LNMAC-induced CSCC lymphatic metastasis. Taken together, these findings indicate that LNMAC plays a crucial role in FGF2-mediated lymphangiogenesis and lymphatic metastasis, highlighting that LNMAC might be a therapeutic target for lymph node metastasis in CSCC patients.
淋巴结是宫颈鳞癌(CSCC)远处转移最常见的部位,这导致预后不良,治疗效果有限。阐明 CSCC 淋巴转移的机制将为 CSCC 的淋巴结转移提供潜在的治疗策略。在这里,基于体内淋巴转移筛选模型,鉴定出一种称为淋巴结转移相关 circRNA(LNMAC)的环状 RNA,其在淋巴转移的 CSCC 中明显上调,并与淋巴结转移相关。LNMAC 的过表达通过诱导淋巴管生成,显著增强 CSCC 细胞向淋巴结的转移能力。在机制上,LNMAC 通过直接与组蛋白乙酰转移酶 1(HDAC1)结合,阻止 Importin α6/8 介导的 HDAC1 核易位,引发组蛋白 H3K27ac 诱导的 FGF2 转录激活,从而表观遗传地上调成纤维细胞生长因子 2(FGF2)的表达。用抗 FGF2 单克隆抗体 3F12E7 治疗可有效抑制 LNMAC 诱导的 CSCC 淋巴转移。总之,这些发现表明 LNMAC 在 FGF2 介导的淋巴管生成和淋巴转移中发挥关键作用,突出表明 LNMAC 可能是 CSCC 患者淋巴结转移的治疗靶点。